Sophie Wildsmith

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Squamous Cell Carcinoma

Risk Assessment

Top Venues

Cancer immunology, immunotherapy : CII

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Tanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, Kevin Harrington, Maura Gillison, Myung-Ju Ahn, Shunji Takahashi, Jared Weiss, Jean-Pascal Machiels, Shrujal Baxi, Valerie Baker, Brent Evans, Nassim Morsli, null Jill Walker, Katia Real, Anne L'Hernault, Amanda Psyrri
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma. Cancer immunology, immunotherapy : CII 73 (4) (2024)
Tanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, Kevin Harrington, Maura Gillison, Myung-Ju Ahn, Shunji Takahashi, Jared Weiss, Jean-Pascal Machiels, Shrujal Baxi, Valerie Baker, Brent Evans, Nassim Morsli, null Jill Walker, Katia Real, Anne L'Hernault, Amanda Psyrri
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma. Cancer immunology, immunotherapy : CII 73 (4) (2024)
Tanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, Kevin Harrington, Maura Gillison, Myung-Ju Ahn, Shunji Takahashi, Jared Weiss, Jean-Pascal Machiels, Shrujal Baxi, Valerie Baker, Brent Evans, Nassim Morsli, null Jill Walker, Katia Real, Anne L'Hernault, Amanda Psyrri
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma. Cancer immunology, immunotherapy : CII 73 (4) (2024)
Tanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, Kevin Harrington, Maura Gillison, Myung-Ju Ahn, Shunji Takahashi, Jared Weiss, Jean-Pascal Machiels, Shrujal Baxi, Valerie Baker, Brent Evans, Nassim Morsli, null Jill Walker, Katia Real, Anne L'Hernault, Amanda Psyrri
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma. Cancer immunology, immunotherapy : CII 73 (4) (2024)
Tanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, Kevin Harrington, Maura Gillison, Myung-Ju Ahn, Shunji Takahashi, Jared Weiss, Jean-Pascal Machiels, Shrujal Baxi, Valerie Baker, Brent Evans, Nassim Morsli, null Jill Walker, Katia Real, Anne L'Hernault, Amanda Psyrri
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma. Cancer immunology, immunotherapy : CII 73 (4) (2024)
Sophie Wildsmith, Weimin Li, Song Wu, Ross Stewart, Nassim Morsli, Rajiv Raja, Qu Zhang, Jiabu Ye, Philip He, Jagdish Shetty, Alejandro Yovine, Nicholas Holoweckyj, Katia Real, Jill Walker, Magdalena Wrona, Melissa de Los Reyes, Craig Barker, Jessica Whiteley, Robert I Haddad, Lisa F Licitra, Matthew J Ferris, Jérôme Fayette, Dan P Zandberg, Lillian L Siu, Ricard Mesía
Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)